TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Drake, C. G. AU - Lipson, E. J. AU - Brahmer, J. R. PY - 2014 DA - 2014// TI - Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2013.208 DO - 10.1038/nrclinonc.2013.208 ID - Drake2014 ER - TY - JOUR AU - Chen, L. AU - Flies, D. B. PY - 2013 DA - 2013// TI - Molecular mechanisms of T cell co-stimulation and co-inhibition JO - Nat Rev Immunol VL - 13 UR - https://doi.org/10.1038/nri3405 DO - 10.1038/nri3405 ID - Chen2013 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - The future of immune checkpoint therapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa8172 DO - 10.1126/science.aaa8172 ID - Sharma2015 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential JO - Cell VL - 161 UR - https://doi.org/10.1016/j.cell.2015.03.030 DO - 10.1016/j.cell.2015.03.030 ID - Sharma2015 ER - TY - JOUR AU - Ledford, H. PY - 2011 DA - 2011// TI - Melanoma drug wins US approval JO - Nature VL - 471 UR - https://doi.org/10.1038/471561a DO - 10.1038/471561a ID - Ledford2011 ER - TY - STD TI - Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. Esmo Open. 2017;2 ID - ref7 ER - TY - STD TI - Marin-Acevedo JA, Soyano AE, Dholaria B, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11 ID - ref8 ER - TY - JOUR AU - Workman, C. J. AU - Dugger, K. J. AU - Vignali, D. A. PY - 2002 DA - 2002// TI - Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3 JO - J Immunol VL - 169 UR - https://doi.org/10.4049/jimmunol.169.10.5392 DO - 10.4049/jimmunol.169.10.5392 ID - Workman2002 ER - TY - JOUR AU - Dholaria, B. AU - Hammond, W. AU - Shreders, A. AU - Lou, Y. PY - 2016 DA - 2016// TI - Emerging therapeutic agents for lung cancer JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0365-z DO - 10.1186/s13045-016-0365-z ID - Dholaria2016 ER - TY - JOUR AU - Anderson, A. C. AU - Joller, N. AU - Kuchroo, V. K. PY - 2016 DA - 2016// TI - Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation JO - Immunity VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.05.001 DO - 10.1016/j.immuni.2016.05.001 ID - Anderson2016 ER - TY - JOUR AU - He, Y. AU - Rivard, C. J. AU - Rozeboom, L. PY - 2016 DA - 2016// TI - Lymphocyte-activation gene-3, an important immune checkpoint in cancer JO - Cancer Sci VL - 107 UR - https://doi.org/10.1111/cas.12986 DO - 10.1111/cas.12986 ID - He2016 ER - TY - JOUR AU - Woo, S. R. AU - Turnis, M. E. AU - Goldberg, M. V. PY - 2012 DA - 2012// TI - Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1620 DO - 10.1158/0008-5472.CAN-11-1620 ID - Woo2012 ER - TY - JOUR AU - Goldberg, M. V. AU - Drake, C. G. PY - 2011 DA - 2011// TI - LAG-3 in cancer immunotherapy JO - Curr Top Microbiol Immunol VL - 344 ID - Goldberg2011 ER - TY - JOUR AU - Andrews, L. P. AU - Marciscano, A. E. AU - Drake, C. G. AU - Vignali, D. A. A. PY - 2017 DA - 2017// TI - LAG3 (CD223) as a cancer immunotherapy target JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12519 DO - 10.1111/imr.12519 ID - Andrews2017 ER - TY - JOUR AU - Brignone, C. AU - Escudier, B. AU - Grygar, C. PY - 2009 DA - 2009// TI - A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-0068 DO - 10.1158/1078-0432.CCR-09-0068 ID - Brignone2009 ER - TY - JOUR AU - Wang-Gillam, A. AU - Plambeck-Suess, S. AU - Goedegebuure, P. PY - 2013 DA - 2013// TI - A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma JO - Investig New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-012-9866-y DO - 10.1007/s10637-012-9866-y ID - Wang-Gillam2013 ER - TY - JOUR AU - Brignone, C. AU - Gutierrez, M. AU - Mefti, F. PY - 2010 DA - 2010// TI - First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity JO - J Transl Med VL - 8 UR - https://doi.org/10.1186/1479-5876-8-71 DO - 10.1186/1479-5876-8-71 ID - Brignone2010 ER - TY - JOUR AU - Nguyen, L. T. AU - Ohashi, P. S. PY - 2015 DA - 2015// TI - Clinical blockade of PD1 and LAG3—potential mechanisms of action JO - Nat Rev Immunol VL - 15 UR - https://doi.org/10.1038/nri3790 DO - 10.1038/nri3790 ID - Nguyen2015 ER - TY - STD TI - Ascierto PA, Melero I, Bhatia S et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol 2017; 35: 9520–9520. ID - ref20 ER - TY - JOUR AU - Sakuishi, K. AU - Ngiow, S. F. AU - Sullivan, J. M. PY - 2013 DA - 2013// TI - TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.23849 DO - 10.4161/onci.23849 ID - Sakuishi2013 ER - TY - JOUR AU - Du, W. AU - Yang, M. AU - Turner, A. PY - 2017 DA - 2017// TI - TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action JO - Int J Mol Sci VL - 18 UR - https://doi.org/10.3390/ijms18030645 DO - 10.3390/ijms18030645 ID - Du2017 ER - TY - JOUR AU - Gorman, J. V. AU - Starbeck-Miller, G. AU - Pham, N. L. PY - 2014 DA - 2014// TI - Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection JO - J Immunol VL - 192 UR - https://doi.org/10.4049/jimmunol.1302290 DO - 10.4049/jimmunol.1302290 ID - Gorman2014 ER - TY - JOUR AU - Ebrahim, A. H. AU - Alalawi, Z. AU - Mirandola, L. PY - 2014 DA - 2014// TI - Galectins in cancer: carcinogenesis, diagnosis and therapy JO - Ann Transl Med VL - 2 ID - Ebrahim2014 ER - TY - JOUR AU - Fiori, V. AU - Magnani, M. AU - Cianfriglia, M. PY - 2012 DA - 2012// TI - The expression and modulation of CEACAM1 and tumor cell transformation JO - Ann Ist Super Sanita VL - 48 UR - https://doi.org/10.4415/ANN_12_02_09 DO - 10.4415/ANN_12_02_09 ID - Fiori2012 ER - TY - STD TI - Ohue Y, Kurose K, Nishio Y et al. Abstract A101: role of TIM-3/Galectin-9 pathway in lung cancer. Cancer Immunol Res 2016; 4: A101-A101. ID - ref26 ER - TY - JOUR AU - Zhu, C. AU - Anderson, A. C. AU - Schubart, A. PY - 2005 DA - 2005// TI - The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity JO - Nat Immunol VL - 6 UR - https://doi.org/10.1038/ni1271 DO - 10.1038/ni1271 ID - Zhu2005 ER - TY - JOUR AU - Yu, X. AU - Harden, K. AU - Gonzalez, L. C. PY - 2009 DA - 2009// TI - The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1674 DO - 10.1038/ni.1674 ID - Yu2009 ER - TY - JOUR AU - Stanietsky, N. AU - Simic, H. AU - Arapovic, J. PY - 2009 DA - 2009// TI - The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0903474106 DO - 10.1073/pnas.0903474106 ID - Stanietsky2009 ER - TY - JOUR AU - Casado, J. G. AU - Pawelec, G. AU - Morgado, S. PY - 2009 DA - 2009// TI - Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-009-0682-y DO - 10.1007/s00262-009-0682-y ID - Casado2009 ER - TY - JOUR AU - Johnston, R. J. AU - Yu, X. AU - Grogan, J. L. PY - 2015 DA - 2015// TI - The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses JO - Oncoimmunology VL - 4 UR - https://doi.org/10.1080/2162402X.2015.1036214 DO - 10.1080/2162402X.2015.1036214 ID - Johnston2015 ER - TY - JOUR AU - Chauvin, J. M. AU - Pagliano, O. AU - Fourcade, J. PY - 2015 DA - 2015// TI - TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80445 DO - 10.1172/JCI80445 ID - Chauvin2015 ER - TY - JOUR AU - Lines, J. L. AU - Pantazi, E. AU - Mak, J. PY - 2014 DA - 2014// TI - VISTA is an immune checkpoint molecule for human T cells JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-1504 DO - 10.1158/0008-5472.CAN-13-1504 ID - Lines2014 ER - TY - JOUR AU - Le Mercier, I. AU - Chen, W. AU - Lines, J. L. PY - 2014 DA - 2014// TI - VISTA regulates the development of protective antitumor immunity JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-1506 DO - 10.1158/0008-5472.CAN-13-1506 ID - Le Mercier2014 ER - TY - JOUR AU - Lines, J. L. AU - Sempere, L. F. AU - Broughton, T. PY - 2014 DA - 2014// TI - VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0072 DO - 10.1158/2326-6066.CIR-14-0072 ID - Lines2014 ER - TY - JOUR AU - Picarda, E. AU - Ohaegbulam, K. C. AU - Zang, X. X. PY - 2016 DA - 2016// TI - Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2428 DO - 10.1158/1078-0432.CCR-15-2428 ID - Picarda2016 ER - TY - JOUR AU - Castellanos, J. R. AU - Purvis, I. J. AU - Labak, C. M. PY - 2017 DA - 2017// TI - B7-H3 role in the immune landscape of cancer JO - American Journal of Clinical and Experimental Immunology VL - 6 ID - Castellanos2017 ER - TY - STD TI - Powderly J, Cote G, Flaherty K et al. Interim results of an ongoing phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunotherapy Cancer 2015; 3: O8-O8. ID - ref38 ER - TY - JOUR AU - Weidle, U. H. AU - Kontermann, R. E. AU - Brinkmann, U. PY - 2014 DA - 2014// TI - Tumor-antigen-binding bispecific antibodies for cancer treatment JO - Semin Oncol VL - 41 UR - https://doi.org/10.1053/j.seminoncol.2014.08.004 DO - 10.1053/j.seminoncol.2014.08.004 ID - Weidle2014 ER - TY - STD TI - Tolcher AW, Alley EW, Chichili G et al. Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. J Clin Oncol 2016; 34: TPS3105-TPS3105. ID - ref40 ER - TY - JOUR AU - Kramer, K. AU - Kushner, B. H. AU - Modak, S. PY - 2010 DA - 2010// TI - Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma JO - J Neuro-Oncol VL - 97 UR - https://doi.org/10.1007/s11060-009-0038-7 DO - 10.1007/s11060-009-0038-7 ID - Kramer2010 ER - TY - JOUR AU - Leone, R. D. AU - Lo, Y. C. AU - Powell, J. D. PY - 2015 DA - 2015// TI - A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy JO - Comput Struct Biotechnol J VL - 13 UR - https://doi.org/10.1016/j.csbj.2015.03.008 DO - 10.1016/j.csbj.2015.03.008 ID - Leone2015 ER - TY - JOUR AU - Zhang, B. PY - 2010 DA - 2010// TI - CD73: a novel target for cancer immunotherapy JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-1544 DO - 10.1158/0008-5472.CAN-10-1544 ID - Zhang2010 ER - TY - STD TI - Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer (vol 17, pg 709, 2017). Nat Rev Cancer 2017; 17: 724–724. ID - ref44 ER - TY - STD TI - Emens L, Powderly J, Fong L, et al. Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors. Cancer Res. 2017;77:CT119. ID - ref45 ER - TY - JOUR AU - Antonioli, L. AU - Novitskiy, S. V. AU - Sachsenmeier, K. F. PY - 2017 DA - 2017// TI - Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies JO - Drug Discov Today VL - 22 UR - https://doi.org/10.1016/j.drudis.2017.06.005 DO - 10.1016/j.drudis.2017.06.005 ID - Antonioli2017 ER - TY - JOUR AU - Paulos, C. M. AU - June, C. H. PY - 2010 DA - 2010// TI - Putting the brakes on BTLA in T cell-mediated cancer immunotherapy JO - J Clin Invest VL - 120 UR - https://doi.org/10.1172/JCI41811 DO - 10.1172/JCI41811 ID - Paulos2010 ER - TY - STD TI - Malissen N, Macagno N, Granjeaud S et al. HVEM: a novel cosignaling molecule of major interest in melanoma. J Clin Oncol 2017; 35: e14591-e14591. ID - ref48 ER - TY - JOUR AU - Lan, X. AU - Li, S. AU - Gao, H. PY - 2017 DA - 2017// TI - Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis JO - Onco Targets Ther VL - 10 UR - https://doi.org/10.2147/OTT.S128825 DO - 10.2147/OTT.S128825 ID - Lan2017 ER - TY - JOUR AU - Massague, J. PY - 2008 DA - 2008// TI - TGF beta in cancer JO - Cell VL - 134 UR - https://doi.org/10.1016/j.cell.2008.07.001 DO - 10.1016/j.cell.2008.07.001 ID - Massague2008 ER - TY - JOUR AU - Wendt, M. K. AU - Tian, M. Z. AU - Schiemann, W. P. PY - 2012 DA - 2012// TI - Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression JO - Cell Tissue Res VL - 347 UR - https://doi.org/10.1007/s00441-011-1199-1 DO - 10.1007/s00441-011-1199-1 ID - Wendt2012 ER - TY - JOUR AU - Thomas, D. A. AU - Massagué, J. PY - 2005 DA - 2005// TI - TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance JO - Cancer Cell VL - 8 UR - https://doi.org/10.1016/j.ccr.2005.10.012 DO - 10.1016/j.ccr.2005.10.012 ID - Thomas2005 ER - TY - JOUR AU - Padua, D. AU - Massague, J. PY - 2009 DA - 2009// TI - Roles of TGF beta in metastasis JO - Cell Res VL - 19 UR - https://doi.org/10.1038/cr.2008.316 DO - 10.1038/cr.2008.316 ID - Padua2009 ER - TY - JOUR AU - Neuzillet, C. AU - Tijeras-Raballand, A. AU - Cohen, R. PY - 2015 DA - 2015// TI - Targeting the TGFbeta pathway for cancer therapy JO - Pharmacol Ther VL - 147 UR - https://doi.org/10.1016/j.pharmthera.2014.11.001 DO - 10.1016/j.pharmthera.2014.11.001 ID - Neuzillet2015 ER - TY - JOUR AU - Smith, A. L. AU - Robin, T. P. AU - Ford, H. L. PY - 2012 DA - 2012// TI - Molecular pathways: targeting the TGF-beta pathway for cancer therapy JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-3224 DO - 10.1158/1078-0432.CCR-11-3224 ID - Smith2012 ER - TY - JOUR AU - Bogdahn, U. AU - Hau, P. AU - Stockhammer, G. PY - 2011 DA - 2011// TI - Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study JO - Neuro-Oncology VL - 13 UR - https://doi.org/10.1093/neuonc/noq142 DO - 10.1093/neuonc/noq142 ID - Bogdahn2011 ER - TY - STD TI - Hwang L, Ng K, Wang W, Trieu VN. OT-101: an anti-TGF-beta-2 antisense-primed tumors to subsequent chemotherapies. J Clin Oncol 2016; 34: e15727-e15727. ID - ref57 ER - TY - STD TI - Gulley JL, Heery CR, Schlom J et al. Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. J Clin Oncol 2017; 35: 3006–3006. ID - ref58 ER - TY - JOUR AU - Brandes, A. A. AU - Carpentier, A. F. AU - Kesari, S. PY - 2016 DA - 2016// TI - A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma JO - Neuro-Oncology VL - 18 UR - https://doi.org/10.1093/neuonc/now009 DO - 10.1093/neuonc/now009 ID - Brandes2016 ER - TY - JOUR AU - Long, E. O. AU - Barber, D. F. AU - Burshtyn, D. N. PY - 2001 DA - 2001// TI - Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158) JO - Immunol Rev VL - 181 UR - https://doi.org/10.1034/j.1600-065X.2001.1810119.x DO - 10.1034/j.1600-065X.2001.1810119.x ID - Long2001 ER - TY - JOUR AU - Dahlberg, C. I. AU - Sarhan, D. AU - Chrobok, M. PY - 2015 DA - 2015// TI - Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00605 DO - 10.3389/fimmu.2015.00605 ID - Dahlberg2015 ER - TY - JOUR AU - Muntasell, A. AU - Ochoa, M. C. AU - Cordeiro, L. PY - 2017 DA - 2017// TI - Targeting NK-cell checkpoints for cancer immunotherapy JO - Curr Opin Immunol VL - 45 UR - https://doi.org/10.1016/j.coi.2017.01.003 DO - 10.1016/j.coi.2017.01.003 ID - Muntasell2017 ER - TY - JOUR AU - Benson, D. M. AU - Caligiuri, M. A. PY - 2014 DA - 2014// TI - Killer immunoglobulin-like receptors and tumor immunity JO - Cancer Immunology Research VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0219 DO - 10.1158/2326-6066.CIR-13-0219 ID - Benson2014 ER - TY - STD TI - Leichner R, Kang H, Haddad R, et al. Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck. Journal for Immunotherapy of Cancer. 2016;4 ID - ref64 ER - TY - STD TI - Schmitt C, Marie-Cardine A, Bensussan A. Therapeutic antibodies to KIR3DL2 and other target antigens on cutaneous T-cell lymphomas. Front Immunol. 2017;8 ID - ref65 ER - TY - JOUR AU - Bagot, M. AU - Porcu, P. AU - Ram-Wolff, C. PY - 2017 DA - 2017// TI - Phase I study of IPH4102, anti-KIR3DL2 Mab, in relapsed/refractory cutaneous T-cell lymphomas (CTCL): dose-escalation safety, biomarker and clinical activity results JO - Hematol Oncol VL - 35 UR - https://doi.org/10.1002/hon.2437_31 DO - 10.1002/hon.2437_31 ID - Bagot2017 ER - TY - JOUR AU - Gyori, D. AU - Chessa, T. AU - Hawkins, P. T. AU - Stephens, L. R. PY - 2017 DA - 2017// TI - Class (I) phosphoinositide 3-kinases in the tumor microenvironment JO - Cancers VL - 9 UR - https://doi.org/10.3390/cancers9030024 DO - 10.3390/cancers9030024 ID - Gyori2017 ER - TY - STD TI - Tolcher A, Hong D, Sullivan R et al. Abstract CT089: IPI-549-01—a phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors. Cancer Res 2017; 77: CT089-CT089. ID - ref68 ER - TY - STD TI - Liu XJ, Kwon H, Li ZH, Fu YX. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol. 2017;10 ID - ref69 ER - TY - JOUR AU - Weiskopf, K. PY - 2017 DA - 2017// TI - Cancer immunotherapy targeting the CD47/SIRP alpha axis JO - Eur J Cancer VL - 76 UR - https://doi.org/10.1016/j.ejca.2017.02.013 DO - 10.1016/j.ejca.2017.02.013 ID - Weiskopf2017 ER - TY - STD TI - Sikic BI, Narayanan S, Colevas AD et al. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 2016; 34: 3019–3019. ID - ref71 ER - TY - STD TI - Thompson JA, Akilov O, Querfeld C et al. A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. J Clin Oncol 2017; 35: TPS3101-TPS3101. ID - ref72 ER - TY - JOUR AU - Willoughby, J. AU - Griffiths, J. AU - Tews, I. AU - Cragg, M. S. PY - 2017 DA - 2017// TI - OX40: structure and function—what questions remain? JO - Mol Immunol VL - 83 UR - https://doi.org/10.1016/j.molimm.2017.01.006 DO - 10.1016/j.molimm.2017.01.006 ID - Willoughby2017 ER - TY - JOUR AU - Aspeslagh, S. AU - Postel-Vinay, S. AU - Rusakiewicz, S. PY - 2016 DA - 2016// TI - Rationale for anti-OX40 cancer immunotherapy JO - Eur J Cancer VL - 52 UR - https://doi.org/10.1016/j.ejca.2015.08.021 DO - 10.1016/j.ejca.2015.08.021 ID - Aspeslagh2016 ER - TY - STD TI - Linch SN, McNamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol. 2015;5 ID - ref75 ER - TY - JOUR AU - Turner, J. G. AU - Rakhmilevich, A. L. AU - Burdelya, L. PY - 2001 DA - 2001// TI - Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells JO - J Immunol VL - 166 UR - https://doi.org/10.4049/jimmunol.166.1.89 DO - 10.4049/jimmunol.166.1.89 ID - Turner2001 ER - TY - JOUR AU - Curti, B. D. AU - Kovacsovics-Bankowski, M. AU - Morris, N. PY - 2013 DA - 2013// TI - OX40 is a potent immune stimulating target in late stage cancer patients JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-4174 DO - 10.1158/0008-5472.CAN-12-4174 ID - Curti2013 ER - TY - STD TI - Infante JR, Hansen AR, Pishvaian MJ et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J Clin Oncol 2016; 34: 101–101. ID - ref78 ER - TY - STD TI - Hamid O, Thompson JA, Diab A et al. First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. J Clin Oncol 2016; 34: 3079–3079. ID - ref79 ER - TY - JOUR AU - Dempke, W. C. M. AU - Fenchel, K. AU - Uciechowski, P. AU - Dale, S. P. PY - 2017 DA - 2017// TI - Second- and third-generation drugs for immuno-oncology treatment-The more the better? JO - Eur J Cancer VL - 74 UR - https://doi.org/10.1016/j.ejca.2017.01.001 DO - 10.1016/j.ejca.2017.01.001 ID - Dempke2017 ER - TY - JOUR AU - Knee, D. A. AU - Hewes, B. AU - Brogdon, J. L. PY - 2016 DA - 2016// TI - Rationale for anti-GITR cancer immunotherapy JO - Eur J Cancer VL - 67 UR - https://doi.org/10.1016/j.ejca.2016.06.028 DO - 10.1016/j.ejca.2016.06.028 ID - Knee2016 ER - TY - STD TI - Koon HB, Shepard DR, Merghoub T et al. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. J Clin Oncol 2016; 34: 3017–3017. ID - ref82 ER - TY - STD TI - Siu LL, Steeghs N, Meniawy T et al. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. J Clin Oncol 2017; 35: 104–104. ID - ref83 ER - TY - STD TI - Tran B, Carvajal RD, Marabelle A et al. Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (pts) with advanced solid tumors. J Clin Oncol 2017; 35: 2521–2521. ID - ref84 ER - TY - JOUR AU - Sanmamed, M. F. AU - Pastor, F. AU - Rodriguez, A. PY - 2015 DA - 2015// TI - Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS JO - Semin Oncol VL - 42 UR - https://doi.org/10.1053/j.seminoncol.2015.05.014 DO - 10.1053/j.seminoncol.2015.05.014 ID - Sanmamed2015 ER - TY - JOUR AU - Fan, X. Z. AU - Quezada, S. A. AU - Sepulveda, M. A. PY - 2014 DA - 2014// TI - Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy JO - J Exp Med VL - 211 UR - https://doi.org/10.1084/jem.20130590 DO - 10.1084/jem.20130590 ID - Fan2014 ER - TY - JOUR AU - Harvey, C. AU - Elpek, K. AU - Duong, E. PY - 2015 DA - 2015// TI - Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics JO - Journal for ImmunoTherapy of Cancer VL - 3 UR - https://doi.org/10.1186/2051-1426-3-S2-O9 DO - 10.1186/2051-1426-3-S2-O9 ID - Harvey2015 ER - TY - STD TI - Burris HA, Callahan MK, Tolcher AW et al. Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC. J Clin Oncol 2017; 35: 3033–3033. ID - ref88 ER - TY - JOUR AU - Chester, C. AU - Ambulkar, S. AU - Kohrt, H. E. PY - 2016 DA - 2016// TI - 4-1BB agonism: adding the accelerator to cancer immunotherapy JO - Cancer Immunol Immunother VL - 65 UR - https://doi.org/10.1007/s00262-016-1829-2 DO - 10.1007/s00262-016-1829-2 ID - Chester2016 ER - TY - JOUR AU - Takeda, K. AU - Kojima, Y. AU - Uno, T. PY - 2010 DA - 2010// TI - Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules JO - J Immunol VL - 184 UR - https://doi.org/10.4049/jimmunol.0903033 DO - 10.4049/jimmunol.0903033 ID - Takeda2010 ER - TY - STD TI - Tolcher AW, Sznol M, Hu-Lieskovan S et al. Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol 2016; 34: 3002–3002. ID - ref91 ER - TY - JOUR AU - Segal, N. H. AU - Logan, T. F. AU - Hodi, F. S. PY - 2017 DA - 2017// TI - Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1272 DO - 10.1158/1078-0432.CCR-16-1272 ID - Segal2017 ER - TY - JOUR AU - Massarelli, E. AU - Segal, N. AU - Ribrag, V. PY - 2016 DA - 2016// TI - Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies JO - J Immunother Cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0113-5 DO - 10.1186/s40425-016-0113-5 ID - Massarelli2016 ER - TY - JOUR AU - Perez-Ruiz, E. AU - Etxeberria, I. AU - Rodriguez-Ruiz, M. E. AU - Melero, I. PY - 2017 DA - 2017// TI - Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1799 DO - 10.1158/1078-0432.CCR-17-1799 ID - Perez-Ruiz2017 ER - TY - JOUR AU - Denoeud, J. AU - Moser, M. PY - 2011 DA - 2011// TI - Role of CD27/CD70 pathway of activation in immunity and tolerance JO - J Leukoc Biol VL - 89 UR - https://doi.org/10.1189/jlb.0610351 DO - 10.1189/jlb.0610351 ID - Denoeud2011 ER - TY - JOUR AU - van de Ven, K. AU - Borst, J. PY - 2015 DA - 2015// TI - Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential JO - Immunotherapy VL - 7 UR - https://doi.org/10.2217/imt.15.32 DO - 10.2217/imt.15.32 ID - van de Ven2015 ER - TY - STD TI - Michot J-M, Maerevoet M, Aftimos PG et al. Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110. J Clin Oncol 2016; 34: 7556–7556. ID - ref97 ER - TY - JOUR AU - Owonikoko, T. K. AU - Hussain, A. AU - Stadler, W. M. PY - 2016 DA - 2016// TI - First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70 JO - Cancer Chemother Pharmacol VL - 77 UR - https://doi.org/10.1007/s00280-015-2909-2 DO - 10.1007/s00280-015-2909-2 ID - Owonikoko2016 ER - TY - STD TI - Sanborn RE, Pishvain MJ, Callahan MK et al. Abstract CT023: phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. Cancer Res 2016; 76: CT023-CT023. ID - ref99 ER - TY - JOUR AU - Vonderheide, R. H. PY - 2007 DA - 2007// TI - Prospect of targeting the CD40 pathway for cancer therapy JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-1893 DO - 10.1158/1078-0432.CCR-06-1893 ID - Vonderheide2007 ER - TY - JOUR AU - Vonderheide, R. H. AU - Glennie, M. J. PY - 2013 DA - 2013// TI - Agonistic CD40 antibodies and cancer therapy JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2064 DO - 10.1158/1078-0432.CCR-12-2064 ID - Vonderheide2013 ER - TY - JOUR AU - Dempke, W. C. M. AU - Fenchel, K. AU - Uciechowski, P. AU - Dale, S. P. PY - 2017 DA - 2017// TI - Second- and third-generation drugs for immuno-oncology treatment-the more the better? JO - Eur J Cancer VL - 74 UR - https://doi.org/10.1016/j.ejca.2017.01.001 DO - 10.1016/j.ejca.2017.01.001 ID - Dempke2017 ER - TY - JOUR AU - Cabo, M. AU - Offringa, R. AU - Zitvogel, L. PY - 2017 DA - 2017// TI - Trial watch: immunostimulatory monoclonal antibodies for oncological indications JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1371896 DO - 10.1080/2162402X.2017.1371896 ID - Cabo2017 ER - TY - JOUR AU - Moon, Y. W. AU - Hajjar, J. AU - Hwu, P. AU - Naing, A. PY - 2015 DA - 2015// TI - Targeting the indoleamine 2,3-dioxygenase pathway in cancer JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0094-9 DO - 10.1186/s40425-015-0094-9 ID - Moon2015 ER - TY - STD TI - Toulmonde M, Penel N, Adam J, et al. Use of pd-1 targeting, macrophage infiltration, and ido pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncology. 2017; ID - ref105 ER - TY - JOUR AU - Bilir, C. AU - Sarisozen, C. PY - 2017 DA - 2017// TI - Indoleamine 2,3-dioxygenase (IDO): only an enzyme or a checkpoint controller? JO - Journal of Oncological Sciences VL - 3 UR - https://doi.org/10.1016/j.jons.2017.04.001 DO - 10.1016/j.jons.2017.04.001 ID - Bilir2017 ER - TY - JOUR AU - Siu, L. L. AU - Gelmon, K. AU - Chu, Q. PY - 2017 DA - 2017// TI - Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/1538-7445.AM2017-CT116 DO - 10.1158/1538-7445.AM2017-CT116 ID - Siu2017 ER - TY - STD TI - Zakharia Y, Drabick JJ, Khleif S et al. Updates on phase 1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. J Clin Oncol 2016; 34: 3075–3075. ID - ref108 ER - TY - STD TI - Bahary N, Garrido-Laguna I, Cinar P et al. Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis. J Clin Oncol 2016; 34: 3020–3020. ID - ref109 ER - TY - STD TI - Jha GG, Gupta S, Tagawa ST et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2017; 35: 3066–3066. ID - ref110 ER - TY - STD TI - Hamid O, Bauer TM, Spira AI et al. Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: phase 2 data from ECHO-202/KEYNOTE-037. J Clin Oncol 2017; 35: 3012–3012. ID - ref111 ER - TY - STD TI - Perez RP, Riese MJ, Lewis KD et al. Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204. J Clin Oncol 2017; 35: 3003–3003. ID - ref112 ER - TY - JOUR AU - Beatty, G. L. AU - Dwyer, P. J. AU - Clark, J. PY - 2017 DA - 2017// TI - First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2272 DO - 10.1158/1078-0432.CCR-16-2272 ID - Beatty2017 ER - TY - JOUR AU - Lu, H. PY - 2014 DA - 2014// TI - TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects JO - Front Immunol VL - 5 ID - Lu2014 ER - TY - JOUR AU - Shi, M. AU - Chen, X. AU - Ye, K. PY - 2016 DA - 2016// TI - Application potential of toll-like receptors in cancer immunotherapy: systematic review JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000003951 DO - 10.1097/MD.0000000000003951 ID - Shi2016 ER - TY - STD TI - Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clinical & Translational Immunology. 2016;5 ID - ref116 ER - TY - JOUR AU - Li, K. AU - Qu, S. AU - Chen, X. PY - 2017 DA - 2017// TI - Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways JO - Int J Mol Sci VL - 18 UR - https://doi.org/10.3390/ijms18020404 DO - 10.3390/ijms18020404 ID - Li2017 ER - TY - STD TI - Gupta S, Grilley-Olson J, Hong D, et al. Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. Cancer Res. 2017;77:CT091. ID - ref118 ER - TY - STD TI - Dredge K, Brennan T, Brown MP et al. An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors. J Clin Oncol 2017; 35: 3083–3083. ID - ref119 ER - TY - STD TI - de la Torre AN, Contractor S, Castaneda I, et al. A phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. Journal of Hepatocellular Carcinoma. 2017;4 ID - ref120 ER - TY - STD TI - Tomala J, Kovar M. IL-2/anti-IL-2 mAb immunocomplexes: a renascence of IL-2 in cancer immunotherapy? Oncoimmunology. 2016;5 ID - ref121 ER - TY - JOUR AU - Jiang, T. AU - Zhou, C. AU - Ren, S. PY - 2016 DA - 2016// TI - Role of IL-2 in cancer immunotherapy JO - Oncoimmunology VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1163462 DO - 10.1080/2162402X.2016.1163462 ID - Jiang2016 ER - TY - STD TI - Su EW, Moore CJ, Suriano S et al. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med 2015; 7: 311ra170-311ra170. ID - ref123 ER - TY - STD TI - Diab A, Tannir NM, Bernatchez C et al. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. J Clin Oncol 2017; 35: e14040-e14040. ID - ref124 ER - TY - STD TI - Bernatchez C, Haymaker CL, Hurwitz ME et al. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. J Clin Oncol 2017; 35: 2545–2545. ID - ref125 ER - TY - JOUR AU - Ananieva, E. PY - 2015 DA - 2015// TI - Targeting amino acid metabolism in cancer growth and anti-tumor immune response JO - World J Biol Chem VL - 6 UR - https://doi.org/10.4331/wjbc.v6.i4.281 DO - 10.4331/wjbc.v6.i4.281 ID - Ananieva2015 ER - TY - JOUR AU - Timosenko, E. AU - Hadjinicolaou, A. V. AU - Cerundolo, V. PY - 2017 DA - 2017// TI - Modulation of cancer-specific immune responses by amino acid degrading enzymes JO - Immunotherapy VL - 9 UR - https://doi.org/10.2217/imt-2016-0118 DO - 10.2217/imt-2016-0118 ID - Timosenko2017 ER - TY - STD TI - Papadopoulos KP, Tsai FY-C, Bauer TM et al. CX-1158-101: a first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors. J Clin Oncol 2017; 35: 3005–3005. ID - ref128 ER - TY - STD TI - Zhou H, Forveille S, Sauvat A, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016;7 ID - ref129 ER - TY - JOUR AU - Sveinbjornsson, B. AU - Camilio, K. A. AU - Haug, B. E. AU - Rekdal, O. PY - 2017 DA - 2017// TI - LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment JO - Future Med Chem VL - 9 UR - https://doi.org/10.4155/fmc-2017-0088 DO - 10.4155/fmc-2017-0088 ID - Sveinbjornsson2017 ER - TY - JOUR AU - Yamazaki, T. AU - Pitt, J. M. AU - Vétizou, M. PY - 2016 DA - 2016// TI - The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade JO - Cell Death Differ VL - 23 UR - https://doi.org/10.1038/cdd.2016.35 DO - 10.1038/cdd.2016.35 ID - Yamazaki2016 ER - TY - STD TI - Spicer JF, Baurain J-F, Awada A et al. LTX-315, an oncolytic peptide, to convert immunogenically ‘cold’ tumors to ‘hot’ in patients with advanced or metastatic tumours: results from an ongoing phase I study. J Clin Oncol 2017; 35: 3085–3085. ID - ref132 ER - TY - JOUR AU - Mittal, S. K. AU - Cho, K. J. AU - Ishido, S. AU - Roche, P. A. PY - 2015 DA - 2015// TI - Interleukin 10 (IL-10)-mediated immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS JO - J Biol Chem VL - 290 UR - https://doi.org/10.1074/jbc.M115.682708 DO - 10.1074/jbc.M115.682708 ID - Mittal2015 ER - TY - JOUR AU - Miotto, D. AU - Lo Cascio, N. AU - Stendardo, M. PY - 2010 DA - 2010// TI - CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer JO - Lung Cancer VL - 69 UR - https://doi.org/10.1016/j.lungcan.2009.12.012 DO - 10.1016/j.lungcan.2009.12.012 ID - Miotto2010 ER - TY - JOUR AU - Zhang, H. AU - Wang, Y. AU - Hwang, E. S. AU - He, Y. W. PY - 2016 DA - 2016// TI - Interleukin-10: an immune-activating cytokine in cancer immunotherapy JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.69.6435 DO - 10.1200/JCO.2016.69.6435 ID - Zhang2016 ER - TY - JOUR AU - Sun, Z. J. AU - Fourcade, J. AU - Pagliano, O. PY - 2015 DA - 2015// TI - IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8(+) T cells JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3016 DO - 10.1158/0008-5472.CAN-14-3016 ID - Sun2015 ER - TY - STD TI - Naing A, Wong DJL, Infante JR et al. PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma. J Clin Oncol 2017; 35: 3084–3084. ID - ref137 ER - TY - JOUR AU - Naidoo, J. AU - Page, D. B. AU - Li, B. T. PY - 2015 DA - 2015// TI - Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies JO - Ann Oncol VL - 26 ID - Naidoo2015 ER - TY - JOUR AU - Michot, J. M. AU - Pruvost, R. AU - Mateus, C. PY - 2018 DA - 2018// TI - Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx701 DO - 10.1093/annonc/mdx701 ID - Michot2018 ER - TY - STD TI - Picchi H, Mateus C, Chouaid C, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2017; ID - ref140 ER - TY - JOUR AU - Champiat, S. AU - Lambotte, O. AU - Barreau, E. PY - 2016 DA - 2016// TI - Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv623 DO - 10.1093/annonc/mdv623 ID - Champiat2016 ER - TY - JOUR AU - Dine, J. AU - Gordon, R. AU - Shames, Y. PY - 2017 DA - 2017// TI - Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer JO - Asia-Pacific Journal of Oncology Nursing VL - 4 UR - https://doi.org/10.4103/apjon.apjon_4_17 DO - 10.4103/apjon.apjon_4_17 ID - Dine2017 ER - TY - STD TI - Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Annals of Translational Medicine. 2016;4 ID - ref143 ER - TY - STD TI - Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406–17. ID - ref144 ER - TY - JOUR AU - Sharma, P. AU - Hu-Lieskovan, S. AU - Wargo, J. A. AU - Ribas, A. PY - 2017 DA - 2017// TI - Primary, adaptive, and acquired resistance to cancer immunotherapy JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.017 DO - 10.1016/j.cell.2017.01.017 ID - Sharma2017 ER - TY - JOUR AU - Zaretsky, J. M. AU - Garcia-Diaz, A. AU - Shin, D. S. PY - 2016 DA - 2016// TI - Mutations associated with acquired resistance to PD-1 blockade in melanoma JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1604958 DO - 10.1056/NEJMoa1604958 ID - Zaretsky2016 ER - TY - JOUR AU - Jenkins, R. W. AU - Barbie, D. A. AU - Flaherty, K. T. PY - 2018 DA - 2018// TI - Mechanisms of resistance to immune checkpoint inhibitors JO - Br J Cancer VL - 118 UR - https://doi.org/10.1038/bjc.2017.434 DO - 10.1038/bjc.2017.434 ID - Jenkins2018 ER - TY - JOUR AU - Taube, J. M. AU - Anders, R. A. AU - Young, G. D. PY - 2012 DA - 2012// TI - Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JO - Sci Transl Med VL - 4 UR - https://doi.org/10.1126/scitranslmed.3003689 DO - 10.1126/scitranslmed.3003689 ID - Taube2012 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Lou, Y. AU - Diao, L. AU - Cuentas, E. R. PY - 2016 DA - 2016// TI - Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1434 DO - 10.1158/1078-0432.CCR-15-1434 ID - Lou2016 ER - TY - JOUR AU - Miao, D. AU - Margolis, C. A. AU - Gao, W. PY - 2018 DA - 2018// TI - Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan5951 DO - 10.1126/science.aan5951 ID - Miao2018 ER - TY - JOUR AU - Luksza, M. AU - Riaz, N. AU - Makarov, V. PY - 2017 DA - 2017// TI - A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy JO - Nature VL - 551 ID - Luksza2017 ER -